Q-omics provides the consensus-scored IGLON5 profile across patient tissues and cancer cell-line models. IGLON5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGLON5 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, IGLON5 RNA expression shows 12,853 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where IGLON5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLON5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLON5 survival associations across molecular data types. IGLON5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLON5 RNA expression–survival associations across cancer types. High IGLON5 expression shows unfavorable associations in KIRP, LIHC, LUAD, BLCA and LUSC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for IGLON5 RNA expression.
This table summarizes IGLON5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLON5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLON5 shows lower tumor expression in LIHC and higher tumor expression in LUAD, KIRC, LUSC, KIRP and UCEC. The LUAD box plot shows higher IGLON5 RNA expression in tumor versus normal tissue (log2 FC = +0.504, t-test p < 0.001).
This table shows molecular features associated with IGLON5 in patient tissues and cancer cell lines. In patient samples, IGLON5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IGLON5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
